» 2008

Animal Health News & Notes for March 14, 2008 3/14/2008

printer friendly version

Brakke Consulting's
Animal Health News & Notes for March 14, 2008

Copyright © Brakke Consulting, Inc.
Editor: Lynn Fondon, DVM, MBA
other news
3i Quoted Private Equity
Anadis Ltd
New Oxford Foods
Phibro Animal Health
Pilgrim's Pride (New Oxford)
Pilgrim's Pride (closures)
Brakke Consulting is pleased to announce the upcoming publication of an all-new report on the US market for small package generic products.  The report will be an in-depth look at a part of the market that intrigues many industry participants.  The report will include such information as:
- the origin and evolution of animal health generics
- estimated market size
- generics use in large vs. small animals
- profiles of generics manufacturers
The report will also include surveys of large and small animal veterinarians and producers, probing their understanding and perception of generic products, current and expected future usage.
The report will be completed in April 2008 and is available for early-order purchase for a price of $7,500 through March 15, 2008.  For more information, contact project manager Dr. Lynn Fondon at lfondon@brakkeconsulting.com
> Investment company 3i Quoted Private Equity Ltd (3i QPE) announced it will buy a 19.5% stake in Phibro Animal Health Corporation, which is planning to list on AIM (the London stock exchange), for $52.7 million.  3i QPE said it will also subscribe for additional common shares of Phibro Animal Health alongside its planned AIM admission, which would take its aggregate shareholding in the animal health and nutrition products maker to 25 to 30%. (Hemscott.com) 
> AgriLabs introduced First Arrival with Encrypt, a feed supplement that enhances the natural immunity of calves, helping them cope with scours. Specially formulated for newborn calves, First Arrival is built around targeted egg-yolk proteins to help combat 11 scour-causing pathogens. It also features Encrypt, an innovative formulation of organic, non-charcoal carbon sources to help improve gut health. (company press release)
> The Hartz Mountain Corporation voluntarily recalled 739 bottles of Hartz Vitamin Care for Cats due to concerns that bottles within the lot may have been potentially contaminated with Salmonella. Hartz recalled another specific lot code of Hartz Vitamin Care for Cats last November due to similar concerns. Both lot codes were manufactured for Hartz by UFAC (USA) Inc. in 2007, and were removed from distribution last November. However, bottles from the second lot had been shipped to customers prior to their having been removed from distribution. Hartz is fully cooperating with the FDA in this voluntary recall. (AnimalNet) 
> Pilgrim's Pride Corp. announced the sale of its turkey production facility and distribution center to New Oxford Foods LLC, a subsidiary of Hain Pure Protein Corp.  Pilgrim's Pride reported total U.S. turkey sales of $122 million for fiscal 2007.  As a result of the sale, Pilgrim's Pride is no longer a producer of turkey, a business it entered in 2001 with the purchase of WLR Foods Inc.  Financial terms were not disclosed.  (Meating Place) 
> Pilgrim's Pride announced it will close a chicken processing complex and six of its 13 distribution centers in the US in response to the crisis facing the US chicken industry from soaring feed-ingredient costs and an oversupply of chicken in the US. (PRNewswire) 
> AUSTRALIA   ImmuCell Corporation announced that it had entered into a cross-license of technology with Anadis Limited of Australia.  ImmuCell granted Anadis an exclusive, worldwide license to the human and environmental applications of its milk antibody technology.  In return, ImmuCell was granted a license to the production technology and capabilities of Anadis in Australia.  ImmuCell is obligated to pay Anadis a royalty on any sales of First Defense manufactured in collaboration with Anadis in Australia. (company press release)  
> US - CANINE CANCER   US researchers have found that genetic changes in dogs with specific blood and bone marrow cancers are virtually identical to genetic abnormalities in humans diagnosed with the same cancers. The researchers plan to use funding from the National Cancer Institute to pinpoint risk factors in certain dog breeds. Because selective breeding preserves a breed's genetics, researchers can study genetic changes associated with cancer more easily in dog populations than in human populations. (Animal Pharm)
> US - MILK LABELING   A coalition of consumer groups and organic dairy producers is mobilizing against a rule proposed by the Ohio Department of Agriculture that would prevent labels from making the hormone distinction unless they also contain the FDA's findings that there is no significant difference between milk produced with or without the recombinant bovine somatotropin hormone. The Pennsylvania Department of Agriculture adopted a similar rule last year, but then reversed course after pressure from consumers and the intervention of the governor. (AnimalNet - Dow Jones)
Pain Management Products for Dogs and Cats - 2008
Coming in April!
Pain management is one of the leading topics in veterinary medicine today.  While pain management products for dogs and cats represented a minor part of the pharmaceuticals market a decade ago, they now represent a substantial market segment with potential still to be tapped. 
Brakke Consulting's annual report on Pain Management Products for Dogs and Cats includes such valuable information as:
  - overview of acute and chronic pain in small animals
  - review of products currently used to treat pain in dogs and cats
  - estimates of US sales and prices of leading pain management products
  - pain management products in development
  - new pain management products
  - review of nutritional supplements used for chronic pain
  - review of therapeutic diets for joint care
  - 2008 survey of small animal veterinarians regarding use of pain management products
Pain Management Products for Dogs and Cats 2008 can be purchased for $4,995 if ordered by March 31, 2008.  The report will be completed in April.  Questions about the study can be answered by project manager Lynn Fondon, DVM, MBA at 972-243-4033, or email Lfondon@brakkeconsulting.com
Generic drugs are a hot topic in animal health these days. Several major, widely-used products have recently gone off patent or will do so in the near future. New generic drug companies have arrived on the scene in the last two or three years. The largest US generic animal health drug manufacturer is likely to be sold in the very near future.
In the human health market, generics represent 67% of total dispensed prescriptions. It's not that high in animal health yet, but it's one of the faster-growing categories.
If you want to learn everything there is to know about generics in animal health, subscribe to Brakke's new study, THE US MARKET FOR ANIMAL HEALTH GENERIC PRODUCTS. You'll be glad you did. Order today and you'll save $1,000 by taking advantage of the early order discount.
Have a great weekend!
John Volk, Chicago
This electronic newsletter is the sole property of Brakke Consulting, Inc.
Any use of the contents herein should be approved by and appropriately attributed to Brakke Consulting, Inc.
For more information about Brakke Consulting's services and syndicated studies, visit our website at www.brakkeconsulting.com.
Brakke Consulting, Inc.
2735 Villa Creek, Suite 140
Dallas, TX  75234    USA